期刊文献+

FISH技术检测宫颈病变中hTERC基因的表达及意义 被引量:1

Expression and significance of hTERC gene by FISH detection in cervical lesions
下载PDF
导出
摘要 目的:检测宫颈癌和宫颈上皮内瘤变中的hTERC基因的扩增情况。方法:采用双色荧光原位杂交技术(FISH)检测100例宫颈病变脱落细胞中的hTERC基因表达。结果:良性细胞学病变、不典型鳞状细胞(ASC)、低度鳞状上皮内瘤变(LSIL)、高度鳞状上皮内瘤变(HSIL)脱落细胞hTERC基因阳性表达率分别为9.09%、25.00%、54.29%、91.67%。慢性宫颈炎、CINⅠ、CINⅡ、CINⅢ和宫颈癌脱落细胞hTERC基因阳性表达率分别为6.67%、14.29%、64.71%、75.00%、90.24%。结论:慢性宫颈炎、CINⅠ、CINⅡ、CINⅢ到宫颈癌的hTERC基因阳性表达率逐渐增高,宫颈低度病变与高度病变hTERC基因检测可成为临床检查宫颈癌的新手段。 Objective: To detect the human telomerase(hTERC)amplication of cervical carcinoma and CIN.Methods: hTERC expression were detected by FISH from 100 cases cervical intraepithelial neoplasia.Results: Rate of expression of hTERC in chronic cervicitis,atypical squamous cells(ASC),low-grade squamous intraepithelial lesion(LSIL),high-grade squamous intraepithelial lesion(HSIL) were 9.09%,25.00%,54.29%,and 91.67%, respectively. Expression rate of hTERC in chronic cercicitis,CINⅠ,CINⅡ,CINⅢ and cervical cancer were 6.67%,14.29%,64.71%,75.00%,and 90.24%,respectively.Conclusion: The positive of hTERC expression is closely related to cervical disease level.FISH may be an adjunct to cytology screening, especially high-risk patients.
出处 《河南医学研究》 CAS 2010年第3期257-259,262,共4页 Henan Medical Research
基金 卫生部科研基金项目(WKJ2007-3-001)
关键词 荧光原位杂交 HTERC基因 宫颈癌 宫颈上皮内瘤变 fluorescence in situ hybridization hTERC gene cervical carcinoma cervical intraepithelial neoplasia
  • 相关文献

参考文献10

  • 1Sen S,Reddy VG,Guleria R,et al.Telomerase-a potenitial molecular maker of lung and cervical[J].Clin Chen Lab Med,2002,40(10):944-1001.
  • 2Anderesson S,Wallin KL,Hellstrom AC,et al.Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcnomas[J].Bitish Journal of Cancer,2006,95(3):331-338.
  • 3张业贵,毕新刚,韩亚玲,蔡岩,徐昕,吴玉鹏,杨壹羚,马建辉,赵平,贾雪梅,王明荣.多色荧光原位杂交在膀胱尿路上皮癌诊断中的应用[J].癌症,2007,26(2):189-193. 被引量:27
  • 4黎静,钟梅.关于卵巢癌遗传学研究技术新进展[J].医学综述,2006,12(23):1440-1442. 被引量:8
  • 5曾瑄,赵大春,周炜洵,武莎斐,梁智勇,刘彤华.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志,2005,34(11):701-705. 被引量:65
  • 6Hopman AHN,Theelen W,Hommelberg PPH,et al.Genomic integration of oncogenic HPV and gain of human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer[J].J Pathol,2006,210(4):412-419.
  • 7李娟,尹格平.子宫颈上皮内瘤变的诊断和治疗进展[J].实用医药杂志,2007,24(10):1248-1250. 被引量:4
  • 8Caraway NP,Khanna A,Dawlett M,et al.Gain of the 3q26 regin in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma[J].Gynecol Onco1,2008,110(1):37-42.
  • 9Sui W,Ou M,Dai,Y,et al.Gain of the human telomerase RAN gene TERC at 3q26 is strongly associated with cervical intraepithelial neoplasia and carcinoma[J].Gynecol Cancer,2009,19(8):1303-1306.
  • 10Andersson S,Sowjanya P,Wangsa D,et al.Detection of genomic amplication of the human telomerase TERC,a potential marker for triage of women with HPV-positive,abnormal Pap smesrs[J].Am J Pathol,2009,175(5):1831-1847.

二级参考文献79

  • 1张志胜 徐立礼 等.阴道镜图谱[M].北京:人民卫生出版社,2000,9..
  • 2Van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).Eur J Cancer, 2001, 37Suppl 1: 11-17.
  • 3Ross JS, Gray GS. Targeted therapy for cancer: the HER-2/neu and Herceptin story. Clin Leadersh Manag Rev, 2003, 17:333-340.
  • 4Vogel-C, Cobieigh MA, Tripathy D? et al. First-line, single-agent Herceptin ( R ) ( trastuzumab ) in metastatic breast cancer: a preliminary report. Eur J Cancer, 2001, 37 Suppl 1:25-29.
  • 5Hammock L, Lewis M, Phillips C, et al. Strong Her-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol, 2005,36 : 1043-1047.
  • 6Ross JS, Fletcher JA, Linette GP, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.Oncologist, 2003, 8:307-325.
  • 7Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol, 2005, 36:250-261.
  • 8Yarden Y. Biology of HER2 and its importance in breast cancer.Oncology, 2001, 61 Suppl 2:1-13.
  • 9Reed W, Hannisdal E, Boehler PJ, et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.Cancer, 2000,88:804-813.
  • 10Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive,node-positive breast cancer. J Clin Oncol, 2000, 18:3471-3479.

共引文献86

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部